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Sir,
We thank doctors Maisonneuve and Lowenfels for their interest in
our work and for their insightful comments. We fully agree that in a
record linkage study with limited covariate information, it is
impossible to clearly distinguish the effects on the underlying
disease from the effects of organ transplantation and subsequent
immunosuppression. As a corollary, we are presently conducting a
series of nested case–control studies within the cohort of organ-
transplanted patients. This will allow us to more directly quantify the
effect of both indication for organ transplantation and subsequent
immunosuppression and other pharmacologic treatment.
There are rather few population-based epidemiological studies
that have explored the relationship between end-stage renal
disease and subsequent development of cancer. There seems to
be a convincing positive association with cancer of the kidney and
bladder. However, in our view, the risk for other malignancies
associated with end-stage renal disease and its different causes
remains to be adequately quantified, since previous studies show
somewhat conflicting results and is hampered by inadequate
power. Another evidence of the impact of organ transplantation
and immune suppressive drugs is the even more pronounced
effects following transplantation of organs other than the kidney.
Also, the relative risk estimates are in general much higher
following organ transplantation compared to end-stage renal
disease, suggesting other mechanisms as well.
Lastly, Maisonneuve and Lowenfels suggest that the differential
misclassification of cervical cancer in the transplantation cohort
compared with the background population accounts for the
absence of excess of cervical cancer. We consider this explanation
unlikely, and the SIR for uterus unspecified supports this view.
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